SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Non-Compliance Means Nasdaq De-Listing In 2024
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
You may also be interested in...
Chinese Firms' Delisting Uncertainty Lifted For Now But Clock Ticking
A new bilateral agreement between securities regulatory authorities in the US and China is being seen as a welcome first step in addressing issues around US inspections of auditors of US-listed Chinese firms, but implementation will be key.
Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal
Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.
LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant
Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.